Sponsor Check › Issuer
Corporation · organized in NEVADA · formed 2022 · RENO, NV · SEC CIK 2066836
Data last updated: Oct 23, 2026, 5:45 PM ET · Latest filing by this issuer: Oct 21, 2026 · Courts (RECAP) last checked: not yet · SEC enforcement last checked: not yet
The five facts investors ask about first. Each section states what was searched and when. Items still in human review are not shown.
Not yet searched.
Sources to be searched: CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Search queued. Results are added automatically; check back later or follow this page to be notified.
Not yet searched.
Sources to be searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. State securities regulator actions: not yet searched. · Search queued. Results are added automatically; check back later or follow this page to be notified.
Not yet searched.
Sources to be searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Search queued. Results are added automatically; check back later or follow this page to be notified.
Coming soon.
What will be compared: what the sponsor says publicly (website, marketing materials, claimed profile) against what public records show — SEC Form D filings, Form ADV adviser registration, and state business records. Every comparison is reviewed by a person before it is published.
No comparisons published yet.
Sources to be compared: sponsor public claims · SEC Form D · SEC Form ADV (IAPD) · state business records · As of Oct 23, 2026, 9:12 PM ET.
0 of 18 offerings report sales commissions; 0 report finder's fees; 0 report proceeds to related persons.
| Source | Offering (latest filing) | Sales commissions | Finder's fees | To insiders | Paid to sell it |
|---|---|---|---|---|---|
| EDGAR ↗ | Jul 2, 2025 D/A File 021-545611 | $0 | $0 | $0 | None listed |
| EDGAR ↗ | Jun 12, 2026 D/A File 021-548921 | $0 | $0 | $0 | None listed |
| EDGAR ↗ | Nov 13, 2025 D File 021-563829 | $0 | $0 | $0 | None listed |
| EDGAR ↗ | Nov 20, 2025 D File 021-564600 | $0 | $0 | $0 | None listed |
| EDGAR ↗ | Feb 4, 2026 D File 021-572364 | $0 | $0 | $0 | None listed |
| EDGAR ↗ | Feb 27, 2026 D File 021-574901 | $0 | $0 | $0 | None listed |
| EDGAR ↗ | Mar 23, 2026 D File 021-577255 | $0 | $0 | $0 | None listed |
| EDGAR ↗ | Apr 1, 2026 D File 021-578656 | $0 | $0 | $0 | None listed |
| EDGAR ↗ | May 21, 2026 D File 021-584842 | $0 | $0 | $0 | None listed |
| EDGAR ↗ | May 21, 2026 D File 021-584843 | $0 | $0 | $0 | None listed |
| EDGAR ↗ | Jun 10, 2026 D File 021-586895 | $0 | $0 | $0 | None listed |
| EDGAR ↗ | Jun 30, 2026 D File 021-589044 | $0 | $0 | $0 | None listed |
| EDGAR ↗ | Jun 30, 2026 D File 021-589046 | $0 | $0 | $0 | None listed |
| EDGAR ↗ | Jul 31, 2026 D File 021-592754 | $0 | $0 | $0 | None listed |
| EDGAR ↗ | Aug 31, 2026 D File 021-595920 | $0 | $0 | $0 | None listed |
| EDGAR ↗ | Sep 15, 2026 D File 021-597545 | $0 | $0 | $0 | None listed |
| EDGAR ↗ | Sep 29, 2026 D File 021-599248 | $0 | $0 | $0 | None listed |
| EDGAR ↗ | Oct 21, 2026 D File 021-601951 | $0 | $0 | $0 | None listed |
As reported by the issuer on Form D (Items 12–15), latest filing per offering. "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates.
Each filing as reported by the issuer. Open a row for the full plain-English detail.
| Filing | Form D filed Oct 21, 2026 SEC file no. 021-601951 · accession 0002060755-26-000061 |
|---|---|
| Raise progress | $1,499,997 sold of $2,999,994 offered (50%) · $1,499,997 remaining Total Offering Amount equals the price of units (499,999 units @ $3.00), plus aggregate exercise price of the warrants forming part of the units (499,999 warrants @ $3.00). |
| Filing timing | Date of first sale: Oct 15, 2026 · Form D filed: Oct 21, 2026 (6 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 9 days (0.0 years) |
| Annual amendments | Issuer reported the offering may last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 2 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 |
| Securities offered | Equity; Option, warrant or other right to acquire; Security to be acquired upon exercise |
| Industry / issuer size | Biotechnology · revenue range: Decline to Disclose |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Stephen Inouye, CFO (Oct 20, 2026) |
| Market context | Minimum investment: $0. Typical range for similar offerings: $10,000–$50,000. Offering size: $2,999,994. Typical range: $2,000,000–$19,999,994. Investors: 2. Typical range: 2–16. "Similar" = Biotechnology offerings claiming 506(b) filed in the last 5 years (3,253 filings); ranges are the middle half (25th–75th percentile). No ranking or score. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the EDGAR daily index |
| Filing | Form D filed Sep 29, 2026 SEC file no. 021-599248 · accession 0002060755-26-000059 |
|---|---|
| Raise progress | $30,875 sold of $30,875 offered (100%) · $0 remaining Total Offering Amount represents the aggregate price of 6,500 shares at a deemed price of $4.75 per share, issued as payment for consulting services. |
| Filing timing | Date of first sale: Sep 23, 2026 · Form D filed: Sep 29, 2026 (6 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 31 days (0.1 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 2 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 |
| Securities offered | Equity |
| Industry / issuer size | Biotechnology · revenue range: Decline to Disclose |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Stephen Inouye, CFO (Sep 28, 2026) |
| Market context | Minimum investment: $0. Typical range for similar offerings: $10,000–$50,000. Offering size: $30,875. Typical range: $2,000,000–$19,999,994. Investors: 2. Typical range: 2–16. "Similar" = Biotechnology offerings claiming 506(b) filed in the last 5 years (3,253 filings); ranges are the middle half (25th–75th percentile). No ranking or score. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set |
| Filing | Form D filed Sep 15, 2026 SEC file no. 021-597545 · accession 0002060755-26-000058 |
|---|---|
| Raise progress | $252,148 sold of $252,148 offered (100%) · $0 remaining Total Offering Amount represents the aggregate price of 1,667 shares at a deemed price of $7.07 per share and 33,500 shares at a deemed price of $7.175 per share, issued as payment for consulting services. |
| Filing timing | Date of first sale: Sep 1, 2026 · Form D filed: Sep 15, 2026 (14 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 53 days (0.1 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 2 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 |
| Securities offered | Equity |
| Industry / issuer size | Biotechnology · revenue range: Decline to Disclose |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Stephen Inouye, CFO (Sep 15, 2026) |
| Market context | Minimum investment: $0. Typical range for similar offerings: $10,000–$50,000. Offering size: $252,148. Typical range: $2,000,000–$19,999,994. Investors: 2. Typical range: 2–16. "Similar" = Biotechnology offerings claiming 506(b) filed in the last 5 years (3,253 filings); ranges are the middle half (25th–75th percentile). No ranking or score. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set |
| Filing | Form D filed Aug 31, 2026 SEC file no. 021-595920 · accession 0002060755-26-000053 |
|---|---|
| Raise progress | $88,548 sold of $88,548 offered (100%) · $0 remaining Total Offering Amount represents the aggregate price of 6,500 shares at a deemed price of $8.89 per share, 3,658 shares at a deemed price of $2.30 per share and 1,601 shares at a deemed price of $13.96 per share, issued as payment for consulting services. |
| Filing timing | Date of first sale: Aug 24, 2026 · Form D filed: Aug 31, 2026 (7 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 61 days (0.2 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 3 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 |
| Securities offered | Equity |
| Industry / issuer size | Biotechnology · revenue range: Decline to Disclose |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Stephen Inouye, CFO (Aug 31, 2026) |
| Market context | Minimum investment: $0. Typical range for similar offerings: $10,000–$50,000. Offering size: $88,548. Typical range: $2,000,000–$19,999,994. Investors: 3. Typical range: 2–16. "Similar" = Biotechnology offerings claiming 506(b) filed in the last 5 years (3,253 filings); ranges are the middle half (25th–75th percentile). No ranking or score. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set |
| Filing | Form D filed Jul 31, 2026 SEC file no. 021-592754 · accession 0002060755-26-000048 |
|---|---|
| Raise progress | $62,725 sold of $62,725 offered (100%) · $0 remaining Total Offering Amount represents the price of 6,500 shares at a deemed price of $9.65 per share, issued as payment for consulting services. |
| Filing timing | Date of first sale: Jul 23, 2026 · Form D filed: Jul 31, 2026 (8 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 93 days (0.3 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 2 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 |
| Securities offered | Equity |
| Industry / issuer size | Biotechnology · revenue range: Decline to Disclose |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Stephen Inouye, CFO (Jul 30, 2026) |
| Market context | Minimum investment: $0. Typical range for similar offerings: $10,000–$50,000. Offering size: $62,725. Typical range: $2,000,000–$19,999,994. Investors: 2. Typical range: 2–16. "Similar" = Biotechnology offerings claiming 506(b) filed in the last 5 years (3,253 filings); ranges are the middle half (25th–75th percentile). No ranking or score. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set |
| Filing | Form D filed Jun 30, 2026 SEC file no. 021-589046 · accession 0002060755-26-000039 |
|---|---|
| Raise progress | $86,320 sold of $86,320 offered (100%) · $0 remaining Total Offering Amount represents the price of 6,500 shares at a deemed price of $13.28 per share, issued as payment for consulting services. |
| Filing timing | Date of first sale: Jun 22, 2026 · Form D filed: Jun 30, 2026 (8 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 124 days (0.3 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 2 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 |
| Securities offered | Equity |
| Industry / issuer size | Biotechnology · revenue range: Decline to Disclose |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Stephen Inouye, CFO (Jun 29, 2026) |
| Market context | Minimum investment: $0. Typical range for similar offerings: $10,000–$50,000. Offering size: $86,320. Typical range: $2,000,000–$19,999,994. Investors: 2. Typical range: 2–16. "Similar" = Biotechnology offerings claiming 506(b) filed in the last 5 years (3,253 filings); ranges are the middle half (25th–75th percentile). No ranking or score. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set |
| Filing | Form D filed Jun 30, 2026 SEC file no. 021-589044 · accession 0002060755-26-000038 |
|---|---|
| Raise progress | $203 sold of $465,953 offered (0%) · $465,750 remaining Total Offering Amount represents the aggregate price of 202,500 warrants @ $0.001 per warrant and the exercise price of these warrants each exercisable at $2.30 per share until June 18, 2029. There is no guarantee that the warrants will be exercised. |
| Filing timing | Date of first sale: Jun 18, 2026 · Form D filed: Jun 30, 2026 (12 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 128 days (0.4 years) |
| Annual amendments | Issuer reported the offering may last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 1 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 |
| Securities offered | Option, warrant or other right to acquire; Security to be acquired upon exercise |
| Industry / issuer size | Biotechnology · revenue range: Decline to Disclose |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Stephen Inouye, CFO (Jun 29, 2026) |
| Market context | Minimum investment: $0. Typical range for similar offerings: $10,000–$50,000. Offering size: $465,953. Typical range: $2,000,000–$19,999,994. Investors: 1. Typical range: 2–16. "Similar" = Biotechnology offerings claiming 506(b) filed in the last 5 years (3,253 filings); ranges are the middle half (25th–75th percentile). No ranking or score. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set |
| Filing | Form D/A (amendment) filed Jun 12, 2026 · amends 0002060755-25-000021 ↗ SEC file no. 021-548921 · accession 0002060755-26-000034 |
|---|---|
| Raise progress | $1,700 sold of $2,200 offered (77%) · $500 remaining Total Offering Amount equals the aggregate price of 1,200,000 shares at $0.001 per share, plus the aggregate exercise price of 1,000,000 warrants exercisable at $0.001 per share. 500,000 warrants currently remain unexercised. |
| Filing timing | Date of first sale: Jun 5, 2025 · Form D filed: Jun 12, 2026 (372 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 506 days (1.4 years) |
| Annual amendments | Issuer reported the offering may last more than one year. This filing is an amendment dated Jun 12, 2026. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 3 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 |
| Securities offered | Equity; Option, warrant or other right to acquire; Security to be acquired upon exercise |
| Industry / issuer size | Biotechnology · revenue range: Decline to Disclose |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Stephen Inouye, CFO (Jun 10, 2026) |
| Changes vs prior filing | total sold: $1,200 → $1,700 investors: 2 → 3 Compared with the D filed Jun 13, 2025 (EDGAR ↗). Amendment history as filed; no conclusion is drawn. |
| Market context | Minimum investment: $0. Typical range for similar offerings: $10,000–$50,000. Offering size: $2,200. Typical range: $2,000,000–$19,999,994. Investors: 3. Typical range: 2–16. "Similar" = Biotechnology offerings claiming 506(b) filed in the last 5 years (3,253 filings); ranges are the middle half (25th–75th percentile). No ranking or score. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set |
| Filing | Form D filed Jun 10, 2026 SEC file no. 021-586895 · accession 0002060755-26-000033 |
|---|---|
| Raise progress | $22,905 sold of $137,427 offered (17%) · $114,522 remaining Total Offering Amount represents the price of 10,002 common shares at a deemed price of $13.74 per share, issued/to be issued as payment for consulting services. 1,667 common shares have been issued and the balance will be issued by October 28, 2026. |
| Filing timing | Date of first sale: May 28, 2026 · Form D filed: Jun 10, 2026 (13 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 149 days (0.4 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 1 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 |
| Securities offered | Equity |
| Industry / issuer size | Biotechnology · revenue range: Decline to Disclose |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Stephen Inouye, CFO (Jun 9, 2026) |
| Market context | Minimum investment: $0. Typical range for similar offerings: $10,000–$50,000. Offering size: $137,427. Typical range: $2,000,000–$19,999,994. Investors: 1. Typical range: 2–16. "Similar" = Biotechnology offerings claiming 506(b) filed in the last 5 years (3,253 filings); ranges are the middle half (25th–75th percentile). No ranking or score. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set |
| Filing | Form D filed May 21, 2026 SEC file no. 021-584843 · accession 0002060755-26-000028 |
|---|---|
| Raise progress | $44,700 sold of $44,700 offered (100%) · $0 remaining Total Offering Amount represents the price of 11,175 common shares at a deemed price of $4.00 per share. |
| Filing timing | Date of first sale: May 14, 2026 · Form D filed: May 21, 2026 (7 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 163 days (0.4 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 1 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 |
| Securities offered | Equity |
| Industry / issuer size | Biotechnology · revenue range: Decline to Disclose |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Stephen Inouye, CFO (May 21, 2026) |
| Market context | Minimum investment: $0. Typical range for similar offerings: $10,000–$50,000. Offering size: $44,700. Typical range: $2,000,000–$19,999,994. Investors: 1. Typical range: 2–16. "Similar" = Biotechnology offerings claiming 506(b) filed in the last 5 years (3,253 filings); ranges are the middle half (25th–75th percentile). No ranking or score. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set |
| Filing | Form D filed May 21, 2026 SEC file no. 021-584842 · accession 0002060755-26-000027 |
|---|---|
| Raise progress | $543 sold of $1,248,634 offered (0%) · $1,248,091 remaining Total Offering Amount represents the aggregated price of 542,648 warrants and the aggregated exercise price of these warrants exercisable at $2.30 per share until May 12, 2029. There is no guarantee that the warrants will be exercised. |
| Filing timing | Date of first sale: May 12, 2026 · Form D filed: May 21, 2026 (9 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 165 days (0.5 years) |
| Annual amendments | Issuer reported the offering may last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 3 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 |
| Securities offered | Option, warrant or other right to acquire; Security to be acquired upon exercise |
| Industry / issuer size | Biotechnology · revenue range: Decline to Disclose |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Stephen Inouye, CFO (May 21, 2026) |
| Market context | Minimum investment: $0. Typical range for similar offerings: $10,000–$50,000. Offering size: $1,248,634. Typical range: $2,000,000–$19,999,994. Investors: 3. Typical range: 2–16. "Similar" = Biotechnology offerings claiming 506(b) filed in the last 5 years (3,253 filings); ranges are the middle half (25th–75th percentile). No ranking or score. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set |
| Filing | Form D filed Apr 1, 2026 SEC file no. 021-578656 · accession 0002060755-26-000022 |
|---|---|
| Raise progress | $1,815,000 sold of $1,815,000 offered (100%) · $0 remaining Total Offering Amount equals the price of 453,750 common shares at $4.00 per share. |
| Filing timing | Date of first sale: Mar 25, 2026 · Form D filed: Apr 1, 2026 (7 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 213 days (0.6 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 8 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 |
| Securities offered | Equity |
| Industry / issuer size | Biotechnology · revenue range: Decline to Disclose |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Stephen Inouye, CFO (Mar 31, 2026) |
| Market context | Minimum investment: $0. Typical range for similar offerings: $10,000–$50,000. Offering size: $1,815,000. Typical range: $2,000,000–$19,999,994. Investors: 8. Typical range: 2–16. "Similar" = Biotechnology offerings claiming 506(b) filed in the last 5 years (3,253 filings); ranges are the middle half (25th–75th percentile). No ranking or score. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set |
| Filing | Form D filed Mar 23, 2026 SEC file no. 021-577255 · accession 0001062993-26-001563 |
|---|---|
| Raise progress | $44,698 sold of $44,698 offered (100%) · $0 remaining Total Offering Amount equals the price of 19,434 common shares at $2.30 per share. |
| Filing timing | Date of first sale: Mar 16, 2026 · Form D filed: Mar 23, 2026 (7 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 222 days (0.6 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 1 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 |
| Securities offered | Equity |
| Industry / issuer size | Biotechnology · revenue range: Decline to Disclose |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Stephen Inouye, CFO (Mar 20, 2026) |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set |
| Filing | Form D filed Feb 27, 2026 SEC file no. 021-574901 · accession 0002060755-26-000015 |
|---|---|
| Raise progress | $467 sold of $1,072,437 offered (0%) · $1,071,970 remaining Total Offering Amount equals the aggregate amount of 466,073 warrants @ $0.001 each and the exercise price of 466,073 warrants @ $2.30 each. The warrants are exercisable until February 11, 2029. There is no guarantee the warrants will be exercised. |
| Filing timing | Date of first sale: Feb 11, 2026 · Form D filed: Feb 27, 2026 (16 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 255 days (0.7 years) |
| Annual amendments | Issuer reported the offering may last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 7 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 |
| Securities offered | Option, warrant or other right to acquire; Security to be acquired upon exercise |
| Industry / issuer size | Biotechnology · revenue range: Decline to Disclose |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Stephen Inouye, CFO (Feb 26, 2026) |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set |
| Filing | Form D filed Feb 4, 2026 SEC file no. 021-572364 · accession 0002060755-26-000011 |
|---|---|
| Raise progress | $810,000 sold of $810,000 offered (100%) · $0 remaining Total Offering Amount equals the price of 352,174 shares at $2.30 per share. |
| Filing timing | Date of first sale: Jan 26, 2026 · Form D filed: Feb 4, 2026 (9 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 271 days (0.7 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 1 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 |
| Securities offered | Equity |
| Industry / issuer size | Biotechnology · revenue range: Decline to Disclose |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Jeff Sharpe, Director (Feb 3, 2026) |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set |
| Filing | Form D filed Nov 20, 2025 SEC file no. 021-564600 · accession 0002060755-25-000059 |
|---|---|
| Raise progress | $202,299 sold of $202,299 offered (100%) · $0 remaining Total Offering Amount equals aggregate price of 87,956 shares at $2.30 per share. |
| Filing timing | Date of first sale: Nov 14, 2025 · Form D filed: Nov 20, 2025 (6 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 344 days (0.9 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 7 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 |
| Securities offered | Equity |
| Industry / issuer size | Biotechnology · revenue range: Decline to Disclose |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Jeff Sharpe, Director (Nov 20, 2025) |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set |
| Filing | Form D filed Nov 13, 2025 SEC file no. 021-563829 · accession 0002060755-25-000054 |
|---|---|
| Raise progress | $2,921,446 sold of $2,921,446 offered (100%) · $0 remaining Total Offering Amount equals aggregate price of 869,566 shares at $2.30 per share and 460,722 shares at $2.00 per share. |
| Filing timing | Date of first sale: Oct 28, 2025 · Form D filed: Nov 13, 2025 (16 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 361 days (1.0 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 5 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 |
| Securities offered | Equity |
| Industry / issuer size | Biotechnology · revenue range: Decline to Disclose |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Jeff Sharpe, Director (Nov 12, 2025) |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set |
| Filing | Form D/A (amendment) filed Jul 2, 2025 · amends 0001062993-25-008936 ↗ SEC file no. 021-545611 · accession 0002060755-25-000024 |
|---|---|
| Raise progress | $1,287,329 sold of $2,531,964 offered (51%) · $1,244,635 remaining Total Offering Amount equals the aggregate price of 19,012,070 shs @ a price between $0.00000289 to $0.20/sh, plus the aggregate exercise price of 957,334 wts @ $0.18/sh, 1,496,880 wts @ $0.187/sh, 3,362,000 wts @ $0.20/sh and 600,000 options @ $0.20/sh. |
| Filing timing | Date of first sale: Apr 10, 2025 · Form D filed: Jul 2, 2025 (83 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 562 days (1.5 years) |
| Annual amendments | Issuer reported the offering may last more than one year. This filing is an amendment dated Jul 2, 2025. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 18 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 |
| Securities offered | Equity; Option, warrant or other right to acquire; Security to be acquired upon exercise |
| Industry / issuer size | Biotechnology · revenue range: Decline to Disclose |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Jeff Sharpe, CEO (Jul 1, 2025) |
| Changes vs prior filing | total offering: $2,411,964 → $2,531,964 Compared with the D filed May 9, 2025 (EDGAR ↗). Amendment history as filed; no conclusion is drawn. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set |
| Filing | Form D filed Jun 13, 2025 SEC file no. 021-548921 · accession 0002060755-25-000021 |
|---|---|
| Raise progress | $1,200 sold of $2,200 offered (55%) · $1,000 remaining Total Offering Amount equals the aggregate price of 1,200,000 shares at $0.001 per share, plus the aggregate exercise price of 1,000,000 warrants exercisable at $0.001 per share. |
| Filing timing | Date of first sale: Jun 5, 2025 · Form D filed: Jun 13, 2025 (8 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 506 days (1.4 years) |
| Annual amendments | Issuer reported the offering may last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 2 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 |
| Securities offered | Equity; Option, warrant or other right to acquire; Security to be acquired upon exercise |
| Industry / issuer size | Biotechnology · revenue range: Decline to Disclose |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Jeff Sharpe, CEO (Jun 13, 2025) |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set |
| Filing | Form D filed May 9, 2025 SEC file no. 021-545611 · accession 0001062993-25-008936 |
|---|---|
| Raise progress | $1,287,329 sold of $2,411,964 offered (53%) · $1,124,635 remaining Total Offering Amount equals the aggregate price of 19,012,070 shares @ a price between $0.00000289 to $0.20 per share, plus the aggregate exercise price of 957,334 warrants @ $0.18/sh, 1,496,880 warrants @ $0.187/sh and 3,362,000 warrants @ $0.20/sh. |
| Filing timing | Date of first sale: Apr 10, 2025 · Form D filed: May 9, 2025 (29 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 562 days (1.5 years) |
| Annual amendments | Issuer reported the offering may last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 18 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 |
| Securities offered | Equity; Option, warrant or other right to acquire; Security to be acquired upon exercise |
| Industry / issuer size | Biotechnology · revenue range: Decline to Disclose |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | David Bogart, Director (May 8, 2025) |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set |
All Form D filings for this CIK on SEC EDGAR ↗. History: 16 new offerings in the last 12 months · most recent filing Oct 21, 2026.
| Name | Relationship | Address state | On filings | Also listed on |
|---|---|---|---|---|
| AARON FARBERG | Director | NV | Oct 21, 2026 | — |
| ANA BASTIANI-POSNER | Director | NV | Oct 21, 2026 | — |
| ANDREW COSTA | Director | NV | Oct 21, 2026 | — |
| APRIL BURKE | Director | NV | Oct 21, 2026 | — |
| BRIAN PILCHER | Executive Officer | NV | Oct 21, 2026 | — |
| CLAUDIA CHAVEZ-MUNOZ | Executive Officer | NV | Oct 21, 2026 | — |
| DAVID R BOGART | Executive Officer, Director | NV | May 9, 2025 → Oct 21, 2026 | — |
| JEFF SHARPE | Director | NV | Oct 21, 2026 | — |
| MILES HARRISON | Executive Officer, Director | NV | Oct 21, 2026 | — |
| SEBASTIAN PURCELL | Director | NV | Oct 21, 2026 | — |
| STEPHEN D INOUYE | Executive Officer | NV | May 9, 2025 → Oct 21, 2026 | — |
| Z PAUL LORENC | Director | NV | Jun 13, 2025 → Oct 21, 2026 | — |
| AARON R FARBERG | Director | NV | Nov 13, 2025 → Sep 29, 2026 | — |
| ANA PAUL BASTIANI-POSNER | Director | NV | Jun 30, 2026 → Sep 29, 2026 | — |
| ANDREW PAUL COSTA | Director | NV | Jun 30, 2026 → Sep 29, 2026 | — |
| APRIL PAUL BURKE | Director | NV | Jun 30, 2026 → Sep 29, 2026 | — |
| BRIAN PAUL PILCHER | Executive Officer | NV | Nov 13, 2025 → Sep 29, 2026 | — |
| CLAUDIA D CHAVEZ-MUNOZ | Executive Officer | NV | Jun 13, 2025 → Sep 29, 2026 | — |
| JEFF D SHARPE | Director | NV | Jun 13, 2025 → Sep 29, 2026 | — |
| MILES R HARRISON | Executive Officer, Director | NV | Nov 13, 2025 → Sep 29, 2026 | — |
| SEBASTIAN PAUL PURCELL | Director | NV | Nov 13, 2025 → Sep 29, 2026 | — |
| BRIAN R PILCHER | Executive Officer, Director | NV | May 9, 2025 → Jul 2, 2025 | — |
| MICHAEL R WRIGHT | Director | NV | May 9, 2025 → Jul 2, 2025 | — |
| CLAUDIA D STEPHEN | Executive Officer | NV | May 9, 2025 | — |
Executive officers, directors and promoters as self-reported by the issuer. Licensed persons: FINRA BrokerCheck ↗ · SEC IAPD ↗.
No other issuers list the same related persons.
Shared address: this business address appears on filings for 10 other issuers. Stated as a count only — many addresses are shared office buildings or registered agents.
Not yet searched. Sources to be searched: SEC Investment Adviser Public Disclosure (IAPD) firm search — registered and exempt reporting advisers · Search queued. Results are added automatically; check back later.
Not yet collected. We store official links only (company website, verified via a profile claim) and the earliest archived date of the website; never personal or family accounts.
Export this report as PDF (all source links + data timestamp; members)
No corrections have been requested for this page.
The complete public-record profile for Conexeu Sciences Inc., plus the weekly new-filings list.
Only "Connect me" shares your details — with this sponsor, at a flat price we charge them, never tied to whether you invest. "Just researching" shares nothing.
Free. Tell us what's wrong and, if you can, where the correct public record is. Every request is logged with its status (received → under review → fixed / confirmed with source).
Sponsors may add a sourced explanation next to any fact on this page. Reviewed before publishing; never edits the public record.
Free. Get the "Claimed by sponsor" chip and a verified contact for corrections. Claiming never changes the public-record section.